Cantor Fitzgerald downgraded Alector (ALEC) to Neutral from Overweight without a price target after the company’s INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly positive benefit. Alector’s other programs are too early to value, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: